|Bid||0.00 x 900|
|Ask||0.00 x 900|
|Day's Range||35.63 - 36.72|
|52 Week Range||20.58 - 40.00|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||731.80|
|Earnings Date||Oct 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.75|
Cardiovascular Systems (CSII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 18, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
If you want to know who really controls Cardiovascular Systems Inc (NASDAQ:CSII), then you’ll have to look at the makeup of its share registry. Institutions often own shares in more Read More...
Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patient in Hong Kong has been treated with its Stealth 360® Peripheral Orbital Atherectomy System (OAS). The Hong Kong case is the first commercial use of Peripheral OAS outside of the United States.
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, Aug. 24, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ADTRAN, ...
Cardiovascular Systems Inc is a medical technology company developing solutions for vascular and coronary disease. Warning! GuruFocus has detected 4 Warning Sign with CSII. For the last quarter Cardiovascular Systems Inc reported a revenue of $59.2 million, compared with the revenue of $52.92 million during the same period a year ago.
The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, presented two-year outcomes from its LIBERTY 360° study in a late-breaking presentation at the 2018 Amputation Prevention Symposium (AMP) in Chicago. The LIBERTY 360° study is designed to evaluate the acute and long-term clinical and economic outcomes of peripheral vascular interventions (PVI) in patients with peripheral artery disease (PAD).
Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that it has signed an agreement with Aerolase Corp. (Aerolase®) to co-develop a new laser atherectomy device for physicians to use in more effectively treating multiple forms of arterial disease. Scott Ward, CSI’s Chairman, President and Chief Executive Officer, said, “We believe there is an opportunity to leverage Aerolase’s innovative proprietary laser technology, which is FDA-cleared for dermatology and medical aesthetic uses, and supported by leading physicians in those fields.
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 83.33% and 1.24%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The St. Paul, Minnesota-based company said it had net income of 11 cents per share. The results exceeded Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Webcast of analyst day on Tuesday, July 31 will begin at 9:00 AM ET with discussion of fiscal fourth-quarter results
Cardiovascular Systems, Inc. (CSI®) (CSII) has signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral Orbital Atherectomy Systems (OAS) outside the United States and Japan. OrbusNeich manufactures and sells an extensive portfolio of coronary and peripheral products including stents, balloons and microcatheters. Scott Ward, Chairman, President and Chief Executive Officer of CSI, said, “We are excited to expand our strategic partnership with OrbusNeich, a globally recognized leader offering an extensive portfolio of vascular intervention products.
Webcast of analyst day on July 31 will include discussion of fiscal fourth-quarter results
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Investors are always looking for growth in small-cap stocks like Cardiovascular Systems Inc (NASDAQ:CSII), with a market cap of US$983.11M. However, an important fact which most ignore is: how financiallyRead More...